Feature | March 29, 2012

TAVI Study Shows Low Mortality, Improved Function at 30 Days

International multicenter ADVANCE study examines outcomes of TAVI at experienced centers

March 29, 2012 — Patients who underwent transcatheter aortic valve implantation (TAVI) at experienced medical centers had significant improvement in valve function as well as low mortality and stroke rates at 30 days, according to research presented this week at the American College of Cardiology (ACC) Annual Scientific Session.

The TAVI procedure includes inserting a bioprosthetic valve through a catheter and implanting it into a diseased native aortic valve. Because it is less invasive than surgical replacement, TAVI has been used for patients with a diseased aortic valve who cannot undergo surgery because of age, left ventricular dysfunction or the presence of coexisting conditions.

The ADVANCE study follows several trials already conducted to determine the safety and effectiveness of TAVI; however, it is the first large TAVI trial to use the Valve Academic Research Consortium’s (VARC) standards to define adverse events. It also used 44 centers that had each performed at least 40 TAVI procedures before joining the trial.

“This study evaluated real-world patients in everyday practice, allowing us to better understand the outcomes of typical use of TAVI,” said lead study author Axel Linke, professor of cardiology at the University of Leipzig Heart Center in Leipzig, Germany. “In addition, this study is one of the most rigorous TAVI studies ever conducted, and it is the first, large multicenter TAVI trial to report findings according to the new standard of evaluation, VARC.”

Between March 2010 and July 2011, a total of 1,015 high-risk patients with severe aortic stenosis were enrolled at 44 centers in 12 countries in Western Europe, Asia and South America. The patients’ mean age was 81 ± six years and 51 percent were female. The patients underwent TAVI and received the CoreValve System. They were then followed to determine the safety and efficacy of the procedure.

The study’s primary endpoint was the occurrence of major adverse cardiac and cerebrovascular events (MACCE), which is a composite of total death, stroke, heart attack and emergent cardiac surgery or percutaneous reintervention. The efficacy of the procedure was also analyzed by measuring valve function.

At the 30-day follow-up point, the researchers found that MACCE occurred in 8.3 percent of patients. The rates of total mortality and cardiac mortality were 4.5 percent and 2.2 percent, respectively, and the stroke rate was 2.9 percent. Life-threatening or disabling bleeding was observed in 4 percent of patients. The research team also found a persistent improvement in aortic valve function, accompanied by a better exercise capacity.

“The study’s conclusion is straightforward — that TAVI is effective and is associated with low mortality in the presence of an improvement in symptoms,” said Linke. “We included patients that were considered high operative risk and non-operable, and they definitely showed symptom improvement. The procedure provided great relief for the patients, as they did much better after implantation.”

The study was funded by Medtronic Inc. Linke disclosed that he is a consultant to Medtronic.

For more information: www.acc.org

Related Content

Xarelto, PMSS, XANTUS, ESC 2015, major bleeding, non-valvular atrial fibrillation, NVAF
News | Antiplatelet and Anticoagulation Therapies| September 04, 2015
Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from PMSS and XANTUS, real-...
ABSORB STEMI TROFI II trial, ESC 2015, bioresorbable vascular scaffold, BVS, STEMI patients

Image courtesy of Abbott Vascular

Feature | Stents Bioresorbable| September 04, 2015
A drug-eluting coronary stent made of absorbable material performed similarly to gold-standard metal among patients...
CUPID 2, gene transfer therapy, heart failure patients, no benefit, ESC 2015, SERCA2a
News | Stem Cell Therapies| September 04, 2015
Gene transfer therapy to correct an enzyme abnormality involved in myocardial contraction and relaxation did not...
News | Cardiac Resynchronization Therapy Devices (CRT)| September 03, 2015
Sorin Group announced the start of patient enrollment in its TRIUMPH-CRT clinical trial in Europe.
CeRtiTuDe cohort study, cardiac resynchronization therapy, CRT-D, CRT-P, ESC 2015
News | Cardiac Resynchronization Therapy Devices (CRT)| September 03, 2015
Most patients with a cardiac resynchronization therapy (CRT) pacemaker would not benefit from the addition of a...
FFR-CT, HeartFlow, PLATFORM trial, ESC 2015, ICA, fractional flow reserve, computed tomography

Image courtesy of HeartFlow Inc.

Feature | FFR Catheters| September 03, 2015
Results of the PLATFORM trial indicate fractional flow reserve computed tomography (FFR-CT) can obviate the need for...
News | Structural Heart| September 02, 2015
An investigational material known as Bioabsorbable Cardiac Matrix (BCM), designed to prevent cardiac remodeling in...
Valtech, cardioband, transcatheter mitral annuloplasty

Valtech's Cardioband transcatheter mitral annuloplasty system in development. It is uses a series of corkscrew anchors, similar to those used on EP implantable device leads, to install the annuloplasty ring to reshape the valve for improved leaflet coaptation.

Feature | Structural Heart| September 02, 2015
September 2, 2015 — HeartWare International Inc.
acute ischemic stroke, larger thrombi retrieval, improved neurological recovery, ESC 2015, MR CLEAN trial, sub-study
Feature | Thrombectomy Devices| September 02, 2015
Retrieval of larger thrombi during intra-arterial treatment (IAT) is associated with improved neurological recovery...
DOPPLER-CIP trial, ESC 2015, heart failure, predictor, small left ventricle, University of Leuven
Feature | Heart Failure| September 02, 2015
Findings presented at the European Society of Cardiology (ESC) Congress 2015 indicate that a small left ventricle with...
Overlay Init